| Title | the effect of ASIV on reversal of taxol resistance |
|---|---|
| Description | To investigate the whether ASIV treatment has a similar effect on transcriptomics with shEREG,we established A549-TR cell lines with shEREG virus. We then performed gene expression profiling analysis using data obtained from RNA-seq of A549-TR or shEREG-A549-TR cells treated with ASIV for 48 hours. |
| Organism | Homo sapiens |
| Data Type | Expression Profiling |
| Data Accessibility | Open-access |
| BioProject | PRJCA016979 |
| Release Date | 2026-04-01 |
| Submitter | Wei Xu (wei-xu11@tsinghua.org.cn) |
| Organization | Shanghai university of traditional chinese medicine |
| Submission Date | 2023-05-14 |
The data cannot be downloaded as it has not yet been registered in the Human Genetic Resource Management Platform of MOST.
| File ID | File Title | Number/Samples | File Type | File Size | File Suffix | Download |
|---|---|---|---|---|---|---|
| OMIX004028-01 | Vehicle_count_replicate1 | 1 | Expression Profiling | 1.7 MB | xlsx | Unavailable |
| OMIX004028-02 | Vehicle_count_replicate2 | 1 | Expression Profiling | 1.7 MB | xlsx | Unavailable |
| OMIX004028-03 | ASIV_count_replicate1 | 1 | Expression Profiling | 1.7 MB | xlsx | Unavailable |
| OMIX004028-04 | ASIV_count_replicate2 | 1 | Expression Profiling | 1.7 MB | xlsx | Unavailable |
| OMIX004028-05 | shEREG_vehicle_count_replicate1 | 1 | Expression Profiling | 1.7 MB | xlsx | Unavailable |
| OMIX004028-06 | shEREG_vehicle_count_replicate2 | 1 | Expression Profiling | 1.7 MB | xlsx | Unavailable |
| OMIX004028-07 | shEREG_ASIV_count_replicate1 | 1 | Expression Profiling | 1.7 MB | xlsx | Unavailable |
| OMIX004028-08 | shEREG_ASIV_count_replicate2 | 1 | Expression Profiling | 1.7 MB | xlsx | Unavailable |
| Paper Title | Journal Name | Publish Time | Accession | Citing Type |
|---|---|---|---|---|
| Inhibition of EREG/ErbB/ERK by Astragaloside IV reversed taxol-resistance of non-small cell lung cancer through attenuation of stemness via TGFβ and Hedgehog signal pathway | Cellular Oncology | 2024-10 | OMIX004028 | Deposit |